Semaglutide intermediate P29
[CAS# 1169630-82-3]

Identification

• Name: Semaglutide intermediate P29
• Synonyms: L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-Glycine
• Molecular Formula: C₁₄₂H₂₁₆N₃₈O₄₅
• Molecular Weight: 3175.46
• CAS Registry Number: 1169630-82-3
• SMILES: O=C(O)CNC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(N)CCC(=O)O)C(O)C)CC=1C=CC=CC1)C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC2=CC=C(O)C=C2)CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC=3C=CC=CC3)C(C)CC)C)CC4=CNC=5C=CC=CC54)CC(C)C)C(C)C)CCCNC(=N)N)CCCNC(=N)N

Properties

• Density: 1.48±0.1 g/cm³

Discovory and Applicatios

Semaglutide intermediate P29 is a key compound in the synthesis of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes mellitus. The discovery of semaglutide intermediate P29 is attributed to extensive research and development efforts by pharmaceutical scientists aiming to enhance the therapeutic properties of GLP-1 analogs. Through chemical modifications and structure-activity relationship studies, semaglutide intermediate P29 was identified as a crucial intermediate compound in the synthesis of semaglutide, allowing for the production of a stable and potent GLP-1 receptor agonist with extended duration of action.

Semaglutide, synthesized using intermediate P29, is indicated for the treatment of type 2 diabetes mellitus to improve glycemic control. As a GLP-1 receptor agonist, semaglutide stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon secretion, slows gastric emptying, and promotes satiety, leading to improved glucose regulation and weight management in patients with type 2 diabetes. Semaglutide formulated with intermediate P29 allows for the development of once-weekly dosing formulations, offering convenience and improved adherence compared to daily injections. Semaglutide, when used as part of comprehensive diabetes management, has demonstrated cardiovascular benefits, including reductions in major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Semaglutide therapy, initiated with intermediate P29, has been associated with clinically significant weight loss in patients with obesity or overweight, regardless of their diabetes status. The appetite-suppressing effects of semaglutide contribute to sustained weight reduction, making it a valuable option for individuals seeking to achieve and maintain weight loss goals. Ongoing research explores the potential of semaglutide and its intermediates, including P29, in novel therapeutic applications beyond diabetes management. Preclinical and clinical studies investigate the efficacy of GLP-1 receptor agonists in the treatment of non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), Alzheimer's disease, and other metabolic and neurodegenerative disorders.